<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Naguib YW</submitter><funding>NCI NIH HHS</funding><pagination>33-48</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5965255</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(1)</volume><pubmed_abstract>In this study, a new compound, 4-(N)-docosahexaenoyl 2', 2'-difluorodeoxycytidine (DHA-dFdC), was synthesized and characterized. Its antitumor activity was evaluated in cell culture and in mouse models of pancreatic cancer. DHA-dFdC is a poorly soluble, pale yellow waxy solid, with a molecular mass of 573.3Da and a melting point of about 96°C. The activation energy for the degradation of DHA-dFdC in an aqueous Tween 80-based solution is 12.86kcal/mol, whereas its stability is significantly higher in the presence of vitamin E. NCI-60 DTP Human Tumor Cell Line Screening revealed that DHA-dFdC has potent and broad-spectrum antitumor activity, especially in leukemia, renal, and central nervous system cancer cell lines. In human and murine pancreatic cancer cell lines, the IC50 value of DHA-dFd</pubmed_abstract><journal>Neoplasia (New York, N.Y.)</journal><pubmed_title>Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.</pubmed_title><pmcid>PMC5965255</pmcid><funding_grant_id>R35 CA197627</funding_grant_id><funding_grant_id>R21 CA179362</funding_grant_id><funding_grant_id>R01 CA135274</funding_grant_id><pubmed_authors>Lashinger LM</pubmed_authors><pubmed_authors>Aldayel AM</pubmed_authors><pubmed_authors>Hursting SD</pubmed_authors><pubmed_authors>Lansakara-P D</pubmed_authors><pubmed_authors>Cui Z</pubmed_authors><pubmed_authors>Valdes S</pubmed_authors><pubmed_authors>Niu M</pubmed_authors><pubmed_authors>Rodriguez BL</pubmed_authors><pubmed_authors>Peng L</pubmed_authors><pubmed_authors>Naguib YW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.</name><description>In this study, a new compound, 4-(N)-docosahexaenoyl 2', 2'-difluorodeoxycytidine (DHA-dFdC), was synthesized and characterized. Its antitumor activity was evaluated in cell culture and in mouse models of pancreatic cancer. DHA-dFdC is a poorly soluble, pale yellow waxy solid, with a molecular mass of 573.3Da and a melting point of about 96°C. The activation energy for the degradation of DHA-dFdC in an aqueous Tween 80-based solution is 12.86kcal/mol, whereas its stability is significantly higher in the presence of vitamin E. NCI-60 DTP Human Tumor Cell Line Screening revealed that DHA-dFdC has potent and broad-spectrum antitumor activity, especially in leukemia, renal, and central nervous system cancer cell lines. In human and murine pancreatic cancer cell lines, the IC50 value of DHA-dFd</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Jan</publication><modification>2025-04-05T10:58:51.953Z</modification><creation>2019-03-26T23:39:21Z</creation></dates><accession>S-EPMC5965255</accession><cross_references><pubmed>26806350</pubmed><doi>10.1016/j.neo.2015.11.012</doi></cross_references></HashMap>